Brought to you by 
Siemens, ViiV continue partnership for companion diagnostics for HIV
09 Feb 2012
Executive Summary
Siemens AG’s Siemens Healthcare Diagnostics Inc. has partnered with ViiV Healthcare and will have commercialization rights to a companion diagnostic for Selzentry (maraviroc), ViiV’s CCR5 co-receptor antagonist for CCR5-tropic HIV.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Siemens, ViiV continue partnership for companion diagnostics for HIV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice